Country: Նոր Զելանդիա
language: անգլերեն
source: Medsafe (Medicines Safety Authority)
Fluorescein sodium 0.25%{relative}; ; Lidocaine hydrochloride monohydrate 4%{relative};
Bausch & Lomb (NZ) Ltd
Fluorescein sodium 0.25% w/v
Eye drops, solution
Active: Fluorescein sodium 0.25%{relative} Lidocaine hydrochloride monohydrate 4%{relative} Excipient: Hydrochloric acid Povidone Water for injection
Single use dropper, 0.5ml, 20 dose units
Prescription
Prescription
ICROM SpA
Package - Contents - Shelf Life: Single use dropper, 0.5ml - 20 dose units - 30 months from date of manufacture stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
1981-09-24
MINIMS ® LIGNOCAINE & FLUORESCEIN EYE DROPS _Lignocaine Hydrochloride & Fluorescein Sodium Eye Drops _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Minims Lignocaine & Fluorescein Eye Drops. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have benefits and risks. Your doctor has weighed the risks of you using Minims Lignocaine & Fluorescein Eye Drops against the benefits they expect it will have for you. IF YOU HAVE ANY CONCERNS ABOUT THIS MEDICINE, ASK YOUR DOCTOR. KEEP THIS LEAFLET IN A SAFE PLACE. You may need to read it again. WHAT MINIMS LIGNOCAINE & FLUORESCEIN EYE DROPS IS USED FOR Minims Lignocaine & Fluorescein Eye Drops contains lignocaine hydrochloride and fluorescein sodium. Lignocaine (also know as lidocaine) belongs to a group of medicines called local anaesthetics, which temporarily numbs the surface of the eye. Fluorescein temporarily colours your eye orange or green and helps your doctor to examine them. Minims Lignocaine & Fluorescein Eye Drops are used to numb and stain the surface of the your eye(s), for a short time only, to allow your doctor to examine your eye. Most often, the eye drops are used to allow the pressure inside your eyes to be measured. ASK YOUR DOCTOR IF YOU HAVE ANY QUESTIONS ABOUT WHY THIS MEDICINE HAS BEEN PRESCRIBED TO YOU. Your doctor may have prescribed it for another reason. BEFORE YOU ARE GIVEN MINIMS LIGNOCAINE & FLUORESCEIN EYE DROPS _WHEN YOU MUST NOT BE GIVEN _ _IT _ DO NOT USE MINIMS LIGNOCAINE & FLUORESCEIN EYE DROPS IF YOU HAVE AN ALLERGY TO: * any medicine containing Lignocaine or Fluorescein * any other local anaesthetic * any of the ingredients listed at the end of this leaflet. Some of the symptoms of an allergic reaction may include: * shortness of breath * wheezing or difficulty breathing * swelling of the face, lips, tongue or other parts of the body * rash, itching or hives on the skin DO NOT USE THIS MEDICINE AF read_full_document
NEW ZEALAND DATA SHEET 1 MINIMS Lidocaine & Fluorescein, eye drops solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 0.5 mL contains 20 mg Lignocaine hydrochloride and 1.25 mg of Fluorescein sodium. For full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Clear, slightly-yellow, slightly viscous, single-use, sterile eye drops. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications As a diagnostic stain and topical anaesthetic combined. Minims Lidocaine & Fluorescein can be used in the measurement of intraocular pressure by Goldmann tonometry. 4.2 Dose and method of administration Adults (including the elderly): One or more drops, as required. Children: As directed by the physician. 4.3 Contraindications Do not use in patients with a known hypersensitivity to fluorescein or lidocaine and other amide-type local anaesthetics. 4.4 Special warnings and precautions for use The anaesthetised eye should be protected from foreign body contamination, particularly in elderly patients in whom the duration of anaesthesia may exceed 30 minutes. Use with caution in an inflamed eye as hyperaemia greatly increases the rate of systemic absorption through the conjunctiva. Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of the drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.) 4.5 Interaction with other medicaments and other forms of interaction None known. NEW ZEALAND DATA SHEET 4.6 Fertility, pregnancy and lactation This combination has been used for a number of years without apparent ill- consequence. 4.7 Effects on ability to drive and use machines None known. 4.8 Undesirable effects ADRs are very rare, (<1/10,000), including isolated reports. Symptoms of allergic-type reactions and anaphylaxis have been reported following topical ophthalmic administration of fluorescein sodium and may manifest as: Eye read_full_document